SCHEMBL10107475

SCHEMBL10107475

CCCCOc1cnc(Cl)c(C)c1C(=O)Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 6/20 0.43
NFKB1 P19838 3/20 0.42
NFKB2 Q00653 3/20 0.42
RELA Q04206 3/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
FAAH O00519 7/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
PTK2B Q14289 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17695310 0.88 LMNA (0.46) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL10107472 0.86 LMNA (0.44) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL10107529 0.85 LMNA (0.46) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL10101770 0.84 MAPT (0.42) CYP2C9CYP2C19TSHRKMT2AMAPT
SCHEMBL10107473 0.84 LMNA (0.43) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL5031267 0.82 LMNA (0.48) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL13082725 0.81 MAPT (0.41) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL10107515 0.81 LMNA (0.44) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL6128440 0.81 LMNA (0.49) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL9286396 0.79 MAPT (0.40) LMNACYP1A2CYP2C9CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828988-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-8367654-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20120108569-A1 8-AZA Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-03 US disclosed
WO-2010129055-A1 8-AZA TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108569-A1 8-AZA Tetracycline Compounds TET1, TET3, HDAC8 LMNA 3433/4885CYP1A2 530/4885CYP2C9 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.